Tesla’s EU sales slump continues; China’s premier warns global trade tensions ‘intensifying’ – business live

Rolling coverage of the latest economic and financial newsThe price of the world’s first malaria vaccine for children in endemic countries will be reduced by more than half, to less than $5, according to the drugmakers GSK and Bharat Biotech.The vaccine, called Mosquirix or RTS,S, was developed by GSK and the non-profit health organisation PATH, and was the first malaria vaccine to be recommended by the World Health Organization in October 2021. It is one of two malaria shots recommended by the WHO.“As an epidemiologist working in malaria vaccine development and delivery, I have seen the impact malaria vaccines are already having on children in high-burden regions of Africa. As a result of the collaboration between the research community in implementing endemic countries, industry, NGOs and multilateral organisations, the world’s first malaria vaccine is helping to reduce all-cause mortality and hospitalisations of severe malaria among children.“Any lower cost vaccine means children in the most affected communities in endemic countries can be protected. Sustained affordability is essential to ensuring that the progress we’ve made in malaria control is not only maintained, but accelerated.” Continue reading...